Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo RG, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Thompson IM Jr, Lara PN Jr. Ryan CW, et al. Among authors: agarwal n. Lancet. 2023 Sep 23;402(10407):1043-1051. doi: 10.1016/S0140-6736(23)00913-3. Epub 2023 Jul 28. Lancet. 2023. PMID: 37524096 Clinical Trial.
Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Sonpavde G, et al. Among authors: agarwal n. Expert Opin Biol Ther. 2011 Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15. Expert Opin Biol Ther. 2011. PMID: 21675925 Review.
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Harshman LC, et al. Among authors: agarwal n. Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8. Lancet Oncol. 2012. PMID: 22877847 Free PMC article.
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; International mRCC Database Consortium. Al-Marrawi MY, et al. Among authors: agarwal n. Target Oncol. 2013 Sep;8(3):203-209. doi: 10.1007/s11523-012-0252-7. Epub 2013 Jan 9. Target Oncol. 2013. PMID: 23300029 Free PMC article.
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. Heng DY, et al. Among authors: agarwal n. Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 9. Lancet Oncol. 2013. PMID: 23312463 Free PMC article.
Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Sivendran S, et al. Among authors: agarwal n. Cancer Treat Rev. 2014 Feb;40(1):190-6. doi: 10.1016/j.ctrv.2013.04.005. Epub 2013 May 16. Cancer Treat Rev. 2014. PMID: 23684373 Free PMC article. Review.
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. Kroeger N, et al. Among authors: agarwal n. Cancer. 2013 Aug 15;119(16):2999-3006. doi: 10.1002/cncr.28151. Epub 2013 May 21. Cancer. 2013. PMID: 23696129 Free PMC article.
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr. Quinn DI, et al. Among authors: agarwal n. Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17. Lancet Oncol. 2013. PMID: 23871417 Free PMC article. Clinical Trial.
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Kroeger N, et al. Among authors: agarwal n. Eur Urol. 2014 Jun;65(6):1086-92. doi: 10.1016/j.eururo.2013.07.031. Epub 2013 Jul 30. Eur Urol. 2014. PMID: 23916693
2,506 results